OARS funding Neuroscience

The complexities of brain and behavior pose fundamental questions in many areas of science and engineering, drawing intense interest across a broad spectrum of disciplinary perspectives while eluding explanation by any one of them. Rapid advances within and across disciplines are leading to an increasingly interwoven fabric of theories, models, empirical methods and findings, and educational approaches, opening new opportunities to understand complex aspects of neural and cognitive systems through integrative multidisciplinary approaches.

It is anticipated that Part 15, Contracting by Negotiations will be used and a single Cost Reimbursement, Level of Effort type contract will be awarded for one 12-month base period and four 12-month option periods on or about 08/06/2018. The purpose of the NIMH PDSP is to provide screening of novel synthetic compounds and natural products for potential use as research tools or probes for basic and clinical research, as therapeutic agents for mental disorders, and as PET, SPECT, and fMRI ligands for functional brain imaging. This program is primarily intended as a screen for compounds that have previously been shown to possess pharmacological, biochemical, or behavioral activities relevant to NIMH and not for the purpose of large-scale, random screening of natural products or combinatorial libraries (e.g., libraries containing >1000 compounds).

The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Proposal of clinical trial research is allowed but not required (optional) for this FOA

The complexities of brain and behavior pose fundamental questions in many areas of science and engineering, drawing intense interest across a broad spectrum of disciplinary perspectives while eluding explanation by any one of them. Rapid advances within and across disciplines are leading to an increasingly interwoven fabric of theories, models, empirical methods and findings, and educational approaches, opening new opportunities to understand complex aspects of neural and cognitive systems through integrative multidisciplinary approaches.

The English Speaking Union of the United States each year sponsors a travel grant for study or research providing a stipend of up to $2,000. This competition is open to qualified under-graduate and post-graduate students, faculty, and others involved in academic pursuits that are in accord with the goal of the English Speaking Union of promoting education and understanding among the English speaking peoples of the world. The grant is designed to assist worthy individuals who are active in the fields of Business, the Humanities, Science and Engineering, Liberal, Fine or Applied Arts and who wish to study or conduct research either in the United States or in one of the countries of the British Commonwealth.

This Funding Opportunity Announcement (FOA) encourages the translation of technologies for brain or behavioral research from academic and other non-small business research sectors to the marketplace. Encouraged from Small Business Concerns (SBCs) are Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnerships and close collaboration between the original developers of these technologies and SBCs, which may be accomplished in any of a number of ways, including the use of multiple program directors/principal investigators.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. The program will utilize the cooperative agreement mechanism to enable milestone-drive projects.

This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery.  Successful applicants will collaborate and conduct the trial within the NIH StrokeNet.  Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support.  The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences.

As part of this mission, the foundation is seeking applications for scientific research projects with the potential to significantly advance the field toward an effective understanding of the mechanisms of cerebrovascular disease. TAAF grants respond to the cerebrovascular community's need for projects that highlight innovative research strategies that will support the development of novel cerebrovascular therapies, clinical management, and recovery for patients.

Made possible through a 12-year, $50 million commitment from the Amgen Foundation, Amgen Scholars allows undergraduates from across the globe to participate in cutting-edge research opportunities at world-class institutions. 17 leading institutions across the U.S., Europe and Japan currently host the summer program. Undergraduate participants benefit from undertaking a research project under top faculty, being part of a cohort-based experience of seminars and networking events, and taking part in a symposium in their respective region (U.S., Europe or Japan) where they meet their peers, learn about biotechnology, and hear from leading scientists. -- No previous research experience is necessary and you do not need to be a biology major to apply. -- You do not need to currently attend one of the 17 host institutions to participate in the program. -- During the program, students work full-time on independent research projects under the guidance of a research scientist. -- Amgen Scholars have opportunities to conduct research, analyze data, present research results, network with other undergraduates with similar research interests, and develop working relationships with faculty mentors and other research staff. -- Financial support is a critical component of the Amgen Scholars Program. Please note that details vary by host institution. See each institution's Amgen Scholars Program website for more information.

The L'Oréal USA For Women in Science fellowship program awards five women postdoctoral scientists annually with grants of $60,000 each for their contributions in Science, Technology, Engineering and Math (STEM) fields and commitment to serving as role models for younger generations. The program is the U.S. component of the L'Oréal-UNESCO For Women in Science International Fellowships program. L'Oréal USA partners with the American Association for the Advancement of Science (AAAS) to manage the program's application and peer-review process. The 2018 L'Oréal USA for Women in Science application period will open December 4th, 2017 and will close on February 2nd, 2018.

The goal of this FOA is to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimer's disease (AD), in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. The causal linkage of AD-associated genetic variants identified in genome-wide association studies and genome sequencing studies to molecular and biological cell phenotypes in human neural cells is expected to give greater insight into molecular targets contributing to the etiology of AD. Studies of human genetics in human cells are essential to understanding the etiology of AD.

A rich body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity.  These findings suggest that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This funding opportunity supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing.

As part of this mission, the foundation is seeking applications for scientific research projects with the potential to significantly advance the field toward an effective understanding of the mechanisms of cerebrovascular disease. TAAF grants respond to the cerebrovascular community's need for projects that highlight innovative research strategies that will support the development of novel cerebrovascular therapies, clinical management, and recovery for patients. To that end, grants of up to $25,000 will be awarded to investigators at any level of experience. However, grant recipients will be expected to present their research at the Aneurysm and AVM Foundation's annual meeting or Awareness Walk event.

The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use. This FOA assumes that 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding context of use is in place Also listed under U44

This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). Also listed under U01.

This funding opportunity (FOA) encourages small business technology transfer STTR research and development of commercial pharmaceutical interventions to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) or Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that propose either basic, clinical, or a combination of basic and clinical studies to investigate how functional changes in the sensory and/or motor systems impact the development and progression of Alzheimer's disease. Studies may include older adults and/or animal models and may employ a variety of approaches, including cellular, molecular, imaging, physiological and genetic, to address this need. For clinical studies, leveraging of existing longitudinal cohorts already collecting sensory and motor assessments is highly encouraged.

The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials.